A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to make laquinimod 0.6 mg available for all subjects who
completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate
the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6
mg in subjects with relapsing multiple sclerosis.